Journal
JOURNAL OF APPLIED GENETICS
Volume -, Issue -, Pages -Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13353-023-00786-4
Keywords
Lung cancer; NSCLC; Immunotherapy; Targeted therapy; CRISPR; Nanoparticles
Ask authors/readers for more resources
Lung cancer, especially nonsmall cell lung cancer (NSCLC), is a highly prevalent and deadly disease worldwide. The treatment for NSCLC has evolved from traditional approaches to more personalized and minimally invasive methods, improving efficacy and reducing side effects. This review discusses established modern approaches such as immunotherapy and targeted therapy, as well as experimental methods like CRISPR and nanoparticles, which offer promising outcomes and faster recovery time for patients.
Lung cancer (LC), particularly nonsmall cell lung cancer (NSCLC), is one of the most prevalent types of neoplasia worldwide, regardless of gender, with the highest mortality rates in oncology. Over the years, treatment for NSCLC has evolved from conventional surgery, chemotherapy, and radiotherapy to more tailored and minimally invasive approaches. The use of personalised therapies has increased the expected efficacy of treatment while simultaneously reducing the frequency of severe adverse effects (AEs). In this review, we discuss established modern approaches, including immunotherapy and targeted therapy, as well as experimental molecular methods like clustered regularly interspaced short palindromic repeat (CRISPR) and nanoparticles. These emerging methods offer promising outcomes and shorten the recovery time for various patients. Recent advances in the diagnostic field, including imaging and genetic profiling, have enabled the implementation of these methods. The versatility of these modern therapies allows for multiple treatment options, such as single-agent use, combination with existing conventional treatments, or incorporation into new regimens. As a result, patients can survive even in the advanced stages of NSCLC, leading to increased survival indicators such as overall survival (OS) and progression-free survival (PFS).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available